Wall Street analysts expect Icon Plc (NASDAQ:ICLR) to announce $1.41 earnings per share for the current quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Icon’s earnings, with the highest EPS estimate coming in at $1.43 and the lowest estimate coming in at $1.38. Icon reported earnings per share of $1.26 during the same quarter last year, which would suggest a positive year-over-year growth rate of 11.9%. The company is expected to announce its next quarterly earnings report on Thursday, February 15th.

According to Zacks, analysts expect that Icon will report full-year earnings of $5.36 per share for the current fiscal year, with EPS estimates ranging from $5.34 to $5.38. For the next financial year, analysts forecast that the business will post earnings of $5.97 per share, with EPS estimates ranging from $5.87 to $6.06. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Icon.

Icon (NASDAQ:ICLR) last released its earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. The business had revenue of $440.30 million during the quarter, compared to the consensus estimate of $438.09 million. Icon had a net margin of 16.37% and a return on equity of 28.42%. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.19 EPS.

A number of equities analysts have issued reports on ICLR shares. Zacks Investment Research upgraded Icon from a “hold” rating to a “buy” rating and set a $120.00 price target on the stock in a report on Thursday, August 24th. ValuEngine upgraded Icon from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Jefferies Group restated a “buy” rating and set a $122.00 price target on shares of Icon in a report on Tuesday, September 12th. Bank of America started coverage on Icon in a report on Monday, September 11th. They set a “buy” rating and a $128.00 price target on the stock. Finally, Robert W. Baird restated a “buy” rating and set a $123.00 price target on shares of Icon in a report on Thursday, October 12th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. Icon has an average rating of “Buy” and an average target price of $121.00.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Fieldpoint Private Securities LLC bought a new position in shares of Icon in the 3rd quarter worth $330,000. Insight Capital Research & Management Inc. bought a new position in shares of Icon in the 3rd quarter worth $1,359,000. Janney Montgomery Scott LLC lifted its holdings in shares of Icon by 11.1% in the 3rd quarter. Janney Montgomery Scott LLC now owns 12,237 shares of the medical research company’s stock worth $1,394,000 after purchasing an additional 1,222 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of Icon by 92.8% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 9,339 shares of the medical research company’s stock worth $1,064,000 after purchasing an additional 4,495 shares in the last quarter. Finally, Vident Investment Advisory LLC lifted its holdings in shares of Icon by 248.8% in the 3rd quarter. Vident Investment Advisory LLC now owns 35,263 shares of the medical research company’s stock worth $4,016,000 after purchasing an additional 25,152 shares in the last quarter. Institutional investors own 89.95% of the company’s stock.

Icon (NASDAQ ICLR) traded down $0.26 during trading hours on Wednesday, reaching $116.55. 211,256 shares of the company’s stock were exchanged, compared to its average volume of 253,436. The firm has a market cap of $6,325.50, a P/E ratio of 22.42, a PEG ratio of 1.80 and a beta of 0.57. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.90 and a quick ratio of 1.90. Icon has a twelve month low of $73.76 and a twelve month high of $124.48.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/12/02/icon-plc-iclr-expected-to-announce-earnings-of-1-41-per-share.html.

Icon Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Get a free copy of the Zacks research report on Icon (ICLR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.